2026-04-01 09:00Group 1: Financial Performance - Revenue reached CNY 14.095 billion, a year-on-year increase of 14.8% [13] - Non-IFRS adjusted net profit was CNY 1.816 billion, up 13.0% year-on-year [13] - Net profit decreased to CNY 1.664 billion, a decline of 7.2% year-on-year [13] - Revenue from TOP 20 pharmaceutical clients grew by 29.4% [13] - New orders increased by over 14% year-on-year [13] Group 2: Business Segments - Revenue composition: 88% from China delivery business, 12% from overseas [16] - Laboratory services accounted for 58% of total revenue [16] - Small molecule CDMO services contributed 25% [16] - Clinical research services made up 14% [16] - Large molecule and CGT services represented 3% [16] Group 3: Client Growth - Global client revenue: North America up 11.0%, Europe up 27.4%, China up 15.7% [17] - Revenue from existing clients increased by 11.7% [19] - New clients accounted for 4% of total revenue [20] Group 4: Operational Highlights - Participated in 887 drug discovery projects [28] - 1,397 ongoing clinical research projects, including 125 Phase III trials [32] - 19 gene therapy CDMO projects, including 1 Phase III and 9 Phase I/II projects [33] Group 5: Future Outlook - The company aims for a revenue growth of 12-18% year-on-year by 2026 [49] - Focus on enhancing CDMO business model and integrating AI and automation technologies [49] - Commitment to sustainable development and improving ESG ratings [21][22]